GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells / Hunan Yongren Medical Innovation, Zhaotai InVivo Biomedicine - LARVOL DELTA

GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: Second Affiliated Hospital of Guangzhou Medical University | Trial completion date: Aug 2026 ➔ Aug 2036 | Trial primary completion date: Aug 2024 ➔ Aug 2026

CAR T-Cell Therapy • IO biomarker • Trial completion date • Trial primary completion date • Lung Cancer • Oncology • Solid Tumor • AXL • CD276 • CLDN18 • EGFR • GPC3 • GUCY2C • HER-2 • MSLN • PSCA • TGFB1